Miscellaneous Data

BORRELIA NEUROTOXIN
Two groups have reported evidence that Borrelia, like several other bacteria, produce neurotoxins. These compounds reportedly can cause many of the symptoms of encephalopathy and also cause an ongoing inflammatory reaction manifested as some of the virus-like symptoms common in late Lyme, as well as potentially interfering with hormone action by blocking hormone receptors. At this time, there is no test available to detect whether or not this compound is present, nor can the amount of toxin be quantified. Indirect measures are currently employed, such as measures of inflammation and hormone resistance. Visit Chronicneurotoxins to perform the VCS test. This is a pattern recognition test that, if abnormal, can reflect dysfunction of the central nervous system. 
It has been said that the longer one is ill with Lyme, the more neurotoxin is present in the body. It probably is stored in fatty tissues, and once present, persists for a very long time. This may be because of what is called an "enterohepatic circulation"-where the toxin is excreted via the bile into the intestinal tract, but then is reabsorbed from the intestinal tract back into the blood stream. This forms the basis for treatment. 

TESTING ISSUES
The Lyme ELISA consistently misses at least 50% of Lyme disease cases due to the assay’s insensitivity and variability with antibiotic treatment [8,9,37,38,46]. It follows that the ‘two-tiered’ testing system endorsed by the Centers for Disease Control and Prevention (CDC), which includes an ELISA screening test followed by a confirmatory Western blot, will also miss 50% of Lyme disease cases because a positive ELISA result is required to proceed to the ‘confirmatory’ Western blot test [38,39]. 

Parenthetically, the CDC criteria were developed for surveillance of Lyme disease, not for diagnostic purposes. This is an important distinction because it is inappropriate to apply surveillance criteria to symptomatic patients whose clinical picture already suggests the presence of Lyme disease. In fact, the clinical case rate for Lyme disease may be as much as 40-times greater than the CDC surveillance case rate [47]. Thus the ‘two-tiered’ testing system is inappropriate for Lyme disease diagnosis. Interpretation of the Lyme Western blot has also been problematic [9,38,48,49]. 

Website Builder